Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells

BackgroundPancreatic cancer is an exceptionally lethal disease with an annual mortality nearly equivalent to its annual incidence. This dismal rate of survival is due to several factors including late presentation with locally advanced, unresectable tumors, early metastatic disease, and rapidly arising chemoresistance. To study the mechanisms of chemoresistance in pancreatic cancer we developed two gemcitabine-resistant pancreatic cancer cell lines.MethodsResistant cells were obtained by culturing L3.6pl and AsPC-1 cells in serially increasing concentrations of gemcitabine. Stable cultures were obtained that were 40- to 50-fold increased in resistance relative to parental cells. Immunofluorescent staining was performed to examine changes in β-catenin and E-cadherin localization. Protein expression was determined by immunoblotting. Migration and invasion were determined by modified Boyden chamber assays. Fluorescence-activated cell sorting (FACS) analyses were performed to examine stem cell markers.ResultsGemcitabine-resistant cells underwent distinct morphological changes, including spindle-shaped morphology, appearance of pseudopodia, and reduced adhesion characteristic of transformed fibroblasts. Gemcitabine-resistant cells were more invasive and migratory. Gemcitabine-resistant cells were increased in vimentin and decreased in E-cadherin expression. Immunofluorescence and immunoblotting revealed increased nuclear localization of total β-catenin. These alterations are hallmarks of epithelial-to-mesenchymal transition (EMT). Resistant cells were activated in the receptor protein tyrosine kinase, c-Met and increased in expression of the stem cell markers CD (cluster of differentiation)24, CD44, and epithelial-specific antigen (ESA).ConclusionsGemcitabine-resistant pancreatic tumor cells are associated with EMT, a more-aggressive and invasive phenotype in numerous solid tumors. The increased phosphorylation of c-Met may also be related to chemoresistance and EMT and presents as an attractive adjunctive chemotherapeutic target in pancreatic cancer.

[1]  G. V. Vande Woude,et al.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network , 1996, Molecular and cellular biology.

[2]  P. Comoglio,et al.  A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth , 2007, Oncogene.

[3]  L. R. Howe,et al.  Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. , 2003, Cancer research.

[4]  中野 靖弘,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007 .

[5]  S. Ariyan,et al.  Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas , 2004, Cancer Research.

[6]  L. Ellis,et al.  Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines , 2006, Clinical Cancer Research.

[7]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[8]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[9]  K. Miyazawa,et al.  Proteolytic activation of hepatocyte growth factor in response to tissue injury. , 1994, The Journal of biological chemistry.

[10]  M. Sharpe,et al.  Scatter factor/hepatocyte growth factor is essential for liver development , 1995, Nature.

[11]  C. Porta.  Drug Resistance in Melanoma: New Perspectives , 2007 .

[12]  J. Dancey,et al.  Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  John G. Collard,et al.  The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model , 2005, Oncogene.

[14]  P. Savagner,et al.  Leaving the neighborhood: molecular mechanisms involved during epithelial‐mesenchymal transition , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  R. Radinsky,et al.  Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated β-catenin , 2004, Clinical & Experimental Metastasis.

[16]  G. Gallick,et al.  Src, chemoresistance and epithelial to mesenchymal transition: are they related? , 2007, Anti-cancer drugs.

[17]  A. Bell,et al.  Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. , 2002, Cancer research.

[18]  A. Bell,et al.  Hepatocyte Growth Factor Induces Wnt-independent Nuclear Translocation of β-Catenin after Met-β-Catenin Dissociation in Hepatocytes , 2002 .

[19]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[20]  W. Jiang,et al.  Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. , 1999, Biochemical and biophysical research communications.

[21]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[22]  G. Christofori,et al.  Hepatocyte growth factor induces cell scattering through MAPK/Egr‐1‐mediated upregulation of Snail , 2006, The EMBO journal.

[23]  R. Nicholson,et al.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839) , 2004, Clinical & Experimental Metastasis.

[24]  R. Nicholson,et al.  Tamoxifen resistance in MCF7 cells promotes EMT‐like behaviour and involves modulation of β‐catenin phosphorylation , 2006, International journal of cancer.

[25]  K. Miyazawa,et al.  Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. , 1994, Cell adhesion and communication.

[26]  L. Ellis,et al.  HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas , 2005, Oncogene.

[27]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[28]  K. Matsumoto,et al.  HGF: its organotrophic role and therapeutic potential. , 1997, Ciba Foundation symposium.

[29]  B. Boyer,et al.  Induction and regulation of epithelial-mesenchymal transitions. , 2000, Biochemical pharmacology.

[30]  K. Miyazawa,et al.  Tyrosine Phosphorylation of β-Catenin and Plakoglobin Enhanced by Hepatocyte Growth Factor and Epidermal Growth Factor in Human Carcinoma Cells , 1994 .

[31]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Trevino,et al.  c-Src Regulates Constitutive and EGF-mediated VEGF Expression in Pancreatic Tumor Cells Through Activation of Phosphatidyl Inositol-3 Kinase and p38 MAPK , 2005, Pancreas.

[33]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[34]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[35]  G. Z. Cheng,et al.  Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.

[36]  C. L. La Porta.  Drug resistance in melanoma: new perspectives. , 2007, Current medicinal chemistry.

[37]  M. Clarke,et al.  Identification of pancreatic cancer stem cells. , 2007, Cancer research.

[38]  A. Donnenberg,et al.  Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis , 2005, Journal of clinical pharmacology.